Search results
Aug 30, 2018 · SOTIO, a biotechnology company owned by the PPF Group, announces today the completion of the acquisition of Cytune Pharma by PPF. SOTIO will continue to develop the lead program SO-C101 (RLI-15) within its pipeline and intends to initiate first-in- human clinical trials in early 2019. SOTIO is spearheading all of PPF’s activities in the ...
- Clinical Trials
Clinical Trials. Currently, SOTIO is conducting three...
- Career
SOTIO is shaping the future of cancer immunotherapies by...
- Pipeline
SOTIO Biotech Inc. 180 Canal St., Suite 300 Boston, MA 02114...
- Clinical Trials
Feb 4, 2015 · SOTIO has facilities in Europe, the United States, China and Russia. For more information about the company visit the website www.sotio.com. Cytune Pharma Cytune Pharma is a private company dedicated to the research and development of a portfolio of novel immunotherapeutic agents which expand and activate immune responses to treat advanced cancers.
Aug 31, 2018 · Under the terms of the acquisition, Sotio will continue to develop Cytune’s lead pipeline molecule SO-C101 (RLI-15) and intends to initiate first-in-human clinical trials early next year (2019). Sotio is fronting all of PPF’s activities in the biotech sector and was closely involved in Cytune’s acquisition process. Additionally, all of ...
Cytune Pharma is a French biotechnology company researching and developing new therapies designed to strengthen the immune response of patients suffering from cancer and infectious diseases. It is member of the SOTIO Biotech group, which develops Interleukin-15-based products based on research of Cytune Pharma.
SOTIO, in collaboration with its partner NBE Therapeutics, is developing oncology candidates based on its platform of potent and highly stable ADCs with an unprecedented therapeutic window. Preclinical data show that these ADCs have a strong efficacy in direct tumor cell killing and a good tolerability profile, but also induce specific antitumor immunity, thereby providing a dual approach to ...
Jun 29, 2016 · Source: Cytune Pharma’s Press Release. Nantes, June 29, 2016 – Cytune Pharma SAS, a French biotechnology company focused on developing novel immunotherapies for the treatment of cancer, announced the closing of a €6M financing round from existing investors. Funds will be used to advance the RLI15 lead program to Phase I clinical trials.
People also ask
What is Soto's role in Cytune Pharma?
What does Sotio do with Cytune Pharma?
What is Sotio's role in Cytune's acquisition of PPF?
Who owns Cytune Pharma?
Sep 7, 2018 · All Cytune projects will be developed as part of SOTIO’s pipeline. Cytune Pharma develops IL-15 based therapies for the treatment of cancer. The lead molecule of Cytune’s pipeline, SO-C101 (RLI-15), is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15Rα and acts as a specific IL-2/IL-15Rβγ agonist.
